NCT05227534 Multi-canceR Early-detection Test in Asymptomatic Individuals (PREVENT)
| NCT ID | NCT05227534 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangzhou Burning Rock Dx Co., Ltd. |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 12,500 participants |
| Start Date | 2022-06-01 |
| Primary Completion | 2024-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 12,500 participants in total. It began in 2022-06-01 with a primary completion date of 2024-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PREVENT is a prospective, multicenter, interventional study evaluating the performance of the OverC multi-cancer detection blood test in asymptomatic individuals with cancer risk.
Eligibility Criteria
Inclusion Criteria: * Participants must be able to provide a written informed consent form * Participants must not have received any colonoscopy, abdominal MRI/CT, low-dose CT, or chest CT within 5 years before signing the informed consent form * Participants must be able to provide blood samples for study tests * Participants must be between 40 and 75 years old Exclusion Criteria: * Individuals who have an acute infection or inflammation within 14 days prior to recruitment * Individuals with cancer-associated clinical symptoms or suspected of cancer * Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant * Recipient of blood transfusion within 7 days prior to recruitment * Individuals who have pure ground-glass opacity * Unable to provide blood samples for the multi-cancer early detection blood test * Individuals who are unable to tolerate standard-of-care cancer screening tests or have contraindications of standard-of-care cancer screening tests * Individuals who have taken medication with anti-tumor effects within 30 days prior to recruitment * Individuals who have received or are undergoing curative cancer treatment within three years prior to recruitment * Individuals with hemorrhagic diseases * Individuals with autoimmune diseases * Individuals who are pregnant or lactating * Individuals who have severe comorbidities that are not suitable for participating in the trial judged by researchers
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05227534 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 75 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05227534 currently recruiting?
Yes, NCT05227534 is actively recruiting participants. Contact the research team at shangli.cai@brbiotech.com for enrollment information.
Where is the NCT05227534 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT05227534 clinical trial?
NCT05227534 is sponsored by Guangzhou Burning Rock Dx Co., Ltd.. The trial plans to enroll 12,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.